PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
October 11, 2023 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023
October 09, 2023 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform
October 04, 2023 07:00 ET
|
PolyPid Ltd.
Safety Profile of D-PLEX100 and PLEX Platform Shown in Juvenile Animals for the First Time Results Could Support Clinical Evaluation of D-PLEX100 in Pediatric Population PETACH TIKVA, Israel, Oct. ...
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 22, 2023 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health
September 21, 2023 07:34 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
PolyPid Announces Reverse Share Split
September 20, 2023 09:15 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Sept. 20, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀
September 19, 2023 07:00 ET
|
PolyPid Ltd.
Company has Successfully Completed the Production of Three Process Validation Batches at Commercial Scale Completes a Substantial Requirement Toward the Planned Submission of D-PLEX100 NDA and MAA...
PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 09, 2023 07:00 ET
|
PolyPid Ltd.
Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Resumed Recruitment into SHIELD II Phase...
PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023
July 26, 2023 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, July 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections
June 29, 2023 08:00 ET
|
PolyPid Ltd.
Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide Range of Bacteria Tested, including Resistant Strains D-PLEX100 Antibacterial Activity Attributed to...